Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Women or men 18 to 75 years of age~2. Greater than 1 year history of episodic, migraine (with or without aura) with onset prior to 50 years of age.~3. Migraine history during the prior 6 months must include:~   1. at least 2 migraines per month~  2. no more than 8 migraines per month~  3. no more than 15 headache days per month~4. Women of child-bearing potential must not be pregnant, must agree to avoid pregnancy and use an acceptable double-barrier method of birth control during the trial.~5. Willing and able to treat a minimum of 2 migraines per month with study medication and consistently complete eDiary for up to 12 months.~Main Exclusion Criteria:~1. Contraindication to triptans~2. Use of selective serotonin reuptake inhibitors (drugs like Prozac®) or serotonin or norepinephrine reuptake inhibitors (drugs like Effexor®) or anti-coagulants (drugs like Coumadin®)~3. Known allergy or sensitivity to zolmitriptan or its derivatives or formulations~4. Known allergy or sensitivity to adhesives and/or titanium~5. Women who are pregnant, breast-feeding or plan a pregnancy during this study~6. Three or more of the following cardiovascular risk factors:~   * Current tobacco use~  * Hypertension or receiving anti-hypertensive medication for hypertension~  * Hyperlipidemia or on prescribed anti-cholesterol treatment~  * Family history of premature coronary artery disease~  * Diabetes mellitus~7. History or current abuse or dependence on alcohol or drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- M207 Microneedle System 3.8 mg (Type: EXPERIMENTAL): M207 Microneedle System 3.8 mg (1.9 mg/patch x 2 patches)

Based on this trial design, predict the completion outcome and termination type (if applicable).